BioLife Solutions announced preliminary unaudited revenue from continuing operations for the fourth quarter and full year 2025.
Fourth quarter revenue increased by 20% compared to the previous year, totaling $24.8 million.
Full year revenue reached $96.2 million, exceeding the high end of the guidance range for FY 2025.
Revenue Growth
Q4 revenue up 20% compared to 2024, full year revenue increased by 29% on a like-for-like basis, mainly from biopreservation products.
Strategic Moves
Shifted to a pure-play cell processing company after divesting certain product lines, which supports long-term value creation.
2026 Outlook
Expect revenue growth and expanding EBITDA margin in 2026, to be accompanied by additional operating leverage.
- BioLife Solutions achieved significant revenue growth in 2025, driven by strategic moves and a focus on high-value products.
- The divestiture of non-core businesses has positioned the company as a specialized player in the CGT market, enhancing profitability and market appeal.
BioLife Solutions' strong financial performance in 2025 and strategic realignment set the stage for continued growth and value creation in 2026 and beyond.